BridgeMD
A study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
EU CTIS ID: 2025-524285-18-00
What this study is testing
Objective response (OR): to evaluate tumor response to BMS‑986504 in participants with advanced/metastatic solid tumors with MTAP gene deletion or MTAP loss. Examine how many participants have their tumors shrinking after treatment.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically confirmed diagnosis of advanced and/or metastatic solid tumor with homozygous deletion of the MTAP gene confirmed
- Participant must be ≥ 18 years at the time of signing the ICF.
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system 8th edition
- Participants must have histologically confirmed advanced gastric (including gastroesophageal junction (GEJ)) adenocarcinoma or squamous esophageal cancer (SEC)
- Participants with histologically confirmed, surgically unresectable locally advanced or metastatic uroepithelial carcinoma that may be accompanied by other histologic differentiation
- Histologically-confirmed supratentorial glioblastoma
You likely can't join if
- Participants must not have spinal cord compression
- Participants must not have active brain metastases or leptomeningeal metastases
- History of gastrointestinal or non-gastrointestinal fistula, gastrointestinal perforation, or intraabdominal abscess
- Cardiac abnormalities including Left Venticular Ejection Fraction
See the full eligibility criteria
- Histologically confirmed diagnosis of advanced and/or metastatic solid tumor with homozygous deletion of the MTAP gene confirmed
- Participant must be ≥ 18 years at the time of signing the ICF.
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system 8th edition
- Participants must have histologically confirmed advanced gastric (including gastroesophageal junction (GEJ)) adenocarcinoma or squamous esophageal cancer (SEC)
- Participants with histologically confirmed, surgically unresectable locally advanced or metastatic uroepithelial carcinoma that may be accompanied by other histologic differentiation
- Histologically-confirmed supratentorial glioblastoma
- Newly-diagnosed histologically-confirmed supratentorial glioblastoma (Grade IV malignant glioma by World Health Organization, including gliosarcoma)
- Histology confirmed Metastatic (Stage IV or recurrent) NSCLC
- Histologically or cytologically confirmed diagnosis of metastatic PDAC
- Participants must not have spinal cord compression
- Participants must not have active brain metastases or leptomeningeal metastases
- History of gastrointestinal or non-gastrointestinal fistula, gastrointestinal perforation, or intraabdominal abscess
- Cardiac abnormalities including Left Venticular Ejection Fraction
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Canada
- China
- United States
- Korea, Republic of
- Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Canada; China; United States; Korea, Republic of; Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.